The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Patient-reported outcomes data from a phase 2 study of idelalisib in patients with refractory indolent B-cell non-Hodgkin lymphoma (iNHL).
Nina D. Wagner-Johnston
Research Funding - Gilead Sciences
Ajay K. Gopal
Research Funding - Gilead Sciences (I)
Brad S. Kahl
Research Funding - Gilead Sciences
Sven De Vos
Research Funding - Gilead Sciences
Stephen J. Schuster
Research Funding - Gilead Sciences
Wojciech Jurczak
Research Funding - Gilead Sciences
Ian Flinn
Research Funding - Gilead Sciences
Christopher Flowers
Research Funding - Gilead Sciences
Peter Martin
Research Funding - Gilead Sciences
Andreas Viardot
Research Funding - Gilead Sciences
Kristie A. Blum
Research Funding - Gilead Sciences
Andre Goy
Research Funding - Gilead Sciences
Andrew John Davies
Research Funding - Gilead Sciences
Pier Luigi Zinzani
Research Funding - Gilead Sciences
Martin H. Dreyling
Research Funding - Gilead Sciences
Lynne I. Wagner
Research Funding - Gilead Sciences
Bess Sorensen
Employment or Leadership Position - Gilead Sciences
Stock Ownership - Gilead Sciences
Wayne Russell Godfrey
Employment or Leadership Position - Gilead Sciences
Stock Ownership - Gilead Sciences
Gilles A. Salles
Research Funding - Gilead Sciences